𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients

✍ Scribed by Filippo Montemurro; Valentina Rossi; Maria Cossu Rocca; Rossella Martinello; Elena Verri; Stefania Redana; Laura Adamoli; Giorgio Valabrega; Anna Sapino; Massimo Aglietta; Giuseppe Viale; Aron Goldhirsch; Franco Nolè

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
223 KB
Volume
118
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant trastuzumab with chemotherapy i
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
✍ Heather L. McArthur; Kathleen M. Mahoney; Patrick G. Morris; Sujata Patil; Linds 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB 👁 1 views

## Abstract ## BACKGROUND: Several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy. However, the benefit for women with small, node‐negative HER2‐positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. Therefore, a

Quantitative HER2 protein levels predict
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
✍ Allan Lipton; Wolfgang J. Köstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB 👁 1 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumab‐treated